Psoriasis: The Evidence-Based Supplement Protocol
Psoriasis is an immune-mediated inflammatory skin disease driven by IL-17/IL-23 pathway activation. Topical corticosteroids, topical vitamin D analogues (calcipotriol), phototherapy, methotrexate, and biologics (TNF-α, IL-17, IL-23 inhibitors) remain primary. Supplements have a modest role as adjuncts targeting the inflammatory and oxidative-stress components.
Vitamin D — Repletion to 30–50 ng/mL
Vitamin D deficiency is common in psoriasis cohorts. The hormone modulates Th17 differentiation — directly relevant to psoriasis pathogenesis. Topical vitamin D analogues (calcipotriol, calcitriol) are evidence-based topical therapy. Oral repletion in deficient adults modestly reduces PASI scores. See vitamin D piece.
EPA-Dominant Omega-3, 2–4 g Daily
A 2014 meta-analysis of 15 RCTs concluded omega-3 modestly reduced PASI scores and erythema-induration-desquamation. Effect smaller than topical or systemic therapy but additive. See omega-3 inflammation context.
Bioavailable Curcumin, 500 mg Twice Daily
Curcumin inhibits NF-κB and modulates IL-17 production. Small RCTs in psoriasis have shown PASI reductions when added to topical therapy. Use bioavailable form. See curcumin piece.
Selenium — Repletion in Deficiency Only
Psoriasis cohorts have lower mean serum selenium than controls. Repletion modestly reduces inflammation in deficient adults. Cap at 200 mcg/day; chronic high selenium has its own toxicity.
What NOT to Take
Avoid "psoriasis cleanse" formulas. Skip megadose biotin — interferes with thyroid lab assays and has no psoriasis evidence. Avoid evening primrose oil — null trial data. Don't replace biologic or methotrexate therapy with supplements alone in moderate-severe disease.
How to Run the Protocol
Topical corticosteroid + topical vitamin D analogue + emollients foundation. Phototherapy or biologic for moderate-severe disease. Test 25-OH-D and selenium. Layer omega-3 2 g + bioavailable curcumin 1 g daily. Add vitamin D and selenium to repletion. Smoking cessation and weight loss reduce psoriasis severity independent of any pharmacology. See condition page.
Sources
- Upala S, Yong WC, Theparee T, Sanguankeo A. "Effect of omega-3 fatty acids on disease severity in patients with psoriasis: a systematic review." International Journal of Rheumatic Diseases, 2017;20(11):1816-1822. PMID: 27943643. DOI: 10.1111/1756-185X.13013.
- Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. "Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris." BioMed Research International, 2015;2015:283634. PMID: 26090395. DOI: 10.1155/2015/283634.
- Stanescu AMA, Simionescu AA, Diaconu CC. "Oral vitamin D therapy in patients with psoriasis." Nutrients, 2021;13(1):163. PMID: 33429884. DOI: 10.3390/nu13010163.
- Michaëlsson G, Berne B, Carlmark B, Strand A. "Selenium in whole blood and plasma is decreased in patients with moderate and severe psoriasis." Acta Dermato-Venereologica, 1989;69(1):29-34. PMID: 2563608.
- Menter A, Strober BE, Kaplan DH, et al. "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics." JAAD, 2019;80(4):1029-1072. PMID: 30772097. DOI: 10.1016/j.jaad.2018.11.057.